Overview

Detailed Summary

Strides Pharma Science Limited is a global pharmaceutical company based in Bengaluru, India. It focuses on manufacturing and exporting a wide range of generic and branded pharmaceutical products.
In Q3FY26, the company achieved its highest ever EBITDA of ₹2,359 million, reflecting a 12.2% year-over-year increase, demonstrating strong operational performance.
Despite a modest revenue growth of 3.6%, the company saw an exceptional 38.6% increase in operational PAT, driven by strong performance in Ex-US markets, which grew by 20% YoY.
The Ex-US markets are becoming increasingly significant, now contributing to 47% of revenue, indicating a strategic shift in the company’s geographical revenue distribution.
Strides Pharma's balance sheet has strengthened, with a reduction in net debt due to effective cash flow management and a focus on high-margin products.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Market Cap: 7,667 Cr
Volatility: High Risk
P/E Ratio: 15.4
Industry P/E: 28.0
PEG Ratio: 0.7
P/B Ratio: 2.8
52W High: 1,024.90
52W Low: 551.00

Sales CAGR

1Y: 17.36%
3Y: 2.63%
5Y: 4.81%
10Y: -0.42%

Profit CAGR

1Y: 3914.56%
3Y: -31.01%
5Y: -13.23%
10Y: -8.53%

ROE

TTM: 14.42%
3Y: 48.60%
5Y: 26.01%
10Y: 18.44%

ROCE

TTM: 14.96%
3Y: 8.70%
5Y: 4.61%
10Y: 5.71%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
VIYASH	202.50	8,791 Cr	116.47	10.39	0.00	15.22	18.17	8.65
STAR	853.20	7,667 Cr	15.38	2.78	0.48	14.42	14.96	8.14
AKUMS	484.85	7,361 Cr	23.33	2.34	0.00	10.07	8.99	6.29
SUDEEPPHRM	583.00	6,592 Cr	45.58	8.03	0.00	20.63	23.80	17.20
BLUEJET	385.00	6,511 Cr	0.28	5.19	0.32	28.06	37.35	19.22
AARTIPHARM	698.00	6,150 Cr	29.62	3.01	0.74	11.72	12.99	6.54
FDC	367.00	6,085 Cr	27.55	2.50	1.34	9.27	12.51	7.51

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	999	1,038	1,084	1,088	1,201	1,154	1,190	1,120	1,221	1,195
Expenses	846	844	854	871	965	943	973	902	989	959
Operating Profit	153	194	230	217	236	210	218	218	232	236
OPM %	15.32	18.68	21.19	19.95	19.63	18.23	18.30	19.48	18.97	19.75
Other Income	-171	-53	-70	-2.82	12	4.14	-12	0.31	17	104
Interest	79	79	80	80	82	52	50	47	46	43
Depreciation	60	51	50	49	51	48	49	49	50	51
Profit Before Tax	-157	10	30	85	115	114	106	122	153	245
Tax %	4.74	100.90	64.99	19.80	18.46	20.91	19.51	13.48	14.10	15.22
Net Profit	-149	-0.09	10	68	94	90	86	106	132	208
EPS in Rs	-14.25	5.40	1.97	7.60	10.10	9.55	8.92	10.81	13.84	21.92

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	2,755	2,845	2,178	2,752	3,316	3,070	3,688	4,051	4,565	4,665
Expenses	2,228	2,431	1,936	2,236	2,681	3,090	3,258	3,308	3,763	3,783
Operating Profit	527	414	242	516	635	-20	430	743	803	882
OPM %	19.14	14.56	11.12	18.75	19.15	-0.65	11.66	18.35	17.58	18.91
Other Income	125	16	17	-132	-3.04	-223	-212	-325	125	3.87
Interest	183	196	79	156	150	177	261	314	249	232
Depreciation	126	154	117	174	206	233	243	221	192	197
Profit Before Tax	343	80	62	55	275	-653	-286	-117	487	457
Tax %	18.48	7.11	-43.04	20.71	11.49	27.32	19.32	-27.01	15.92	17.99
Net Profit	280	74	89	43	244	-474	-231	-149	409	375
EPS in Rs	43.30	71.95	35.21	3.95	29.12	-49.95	-21.97	-7.65	36.16	55.49
Dividend Payout %	10.08	2.69	8.28	344.83	8.36	0.00	-6.67	-32.22	1.02	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	89	89	90	90	90	90	90	90	92	92
Reserves	2,774	2,659	2,374	2,559	2,438	2,687	2,269	2,122	2,034	2,460
Borrowings	3,447	3,032	2,496	3,148	2,106	2,348	3,025	3,030	2,517	1,880
Other Liabilities	1,349	2,324	1,749	2,183	1,519	1,890	1,592	1,397	1,197	1,617
Total Liabilities	7,659	8,105	6,708	7,980	6,152	7,015	6,976	6,638	5,840	6,049
Fixed Assets	2,424	2,909	2,903	3,570	2,026	2,151	2,333	2,298	1,853	1,888
CWIP	1,200	780	620	453	413	447	291	151	162	207
Investments	1,304	1,595	662	779	622	766	554	502	315	420
Other Assets	2,731	2,821	2,524	3,177	3,091	3,651	3,798	3,687	3,510	3,533
Total Assets	7,659	8,105	6,708	7,980	6,152	7,015	6,976	6,638	5,840	6,049

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	72	288	187	60	205	481	-258	44	701	684
Cash from Investing Activity	-2,213	-1,225	567	-148	1,306	-521	-119	302	-150	-90
Cash from Financing Activity	2,949	338	-1,016	194	-1,709	-16	421	-214	-693	-643
Net Cash Flow	807	-599	-261	106	-199	-55	45	133	-143	-48

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	28.27%	28.07%	27.79%	27.39%	25.88%	25.86%	25.84%	26.82%	28.30%	28.30%	27.86%	27.86%
FIIs	18.85%	16.73%	17.20%	19.45%	24.57%	26.71%	30.08%	28.48%	28.32%	28.02%	28.51%	29.52%
DIIs	18.30%	20.01%	19.97%	19.42%	18.05%	18.56%	18.25%	16.93%	13.73%	13.31%	12.99%	13.03%
Public	34.58%	35.19%	35.05%	33.74%	31.50%	28.87%	25.83%	27.77%	29.65%	30.37%	30.64%	29.59%
Total Shareholders	1,20,916	1,12,775	1,01,638	91,182	84,695	91,917	96,009	1,14,237	95,125	92,889	91,206	85,589

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Available on Pro Plan